Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Inhibition of IL-23 mediated inflammation with a novel small molecule inverse agonist of RORgt.

Gauld S, Jacquet S, Gauvin D, Wallace C, Wang Y, McCarthy R, Goess C, Leys L, Huang S, Su Z, Edelmayer R, Wetter J, Salte K, McGaraughty S, Argiriadi M, Honore P, Luccarini JM, Bressac D, Desino K, Breinlinger E, Cusack K, Potin D, Kort M, Masson P.

J Pharmacol Exp Ther. 2019 Aug 2. pii: jpet.119.258046. doi: 10.1124/jpet.119.258046. [Epub ahead of print]

2.

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORĪ³ inverse agonists.

Amaudrut J, Argiriadi MA, Barth M, Breinlinger EC, Bressac D, Broqua P, Calderwood DJ, Chatar M, Cusack KP, Gauld SB, Jacquet S, Kamath RV, Kort ME, Lepais V, Luccarini JM, Masson P, Montalbetti C, Mounier L, Potin D, Poupardin O, Rouaud S, Spitzer L, Wallace CD.

Bioorg Med Chem Lett. 2019 Jul 15;29(14):1799-1806. doi: 10.1016/j.bmcl.2019.05.015. Epub 2019 May 9.

PMID:
31101472
3.

Artificial cardiac pacemaker placement in dogs with a cohort of myocarditis suspects and association of ultrasensitive cardiac troponin I with survival.

Wesselowski S, Cusack K, Gordon SG, Jeffery N, Saunders AB.

J Vet Cardiol. 2019 Apr;22:84-95. doi: 10.1016/j.jvc.2018.09.003. Epub 2018 Dec 18.

PMID:
30573438
4.

Prodrugs for colon-restricted delivery: Design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors.

George DM, Huntley RJ, Cusack K, Duignan DB, Hoemann M, Loud J, Mario R, Melim T, Mullen K, Somal G, Wang L, Edmunds JJ.

PLoS One. 2018 Sep 7;13(9):e0203567. doi: 10.1371/journal.pone.0203567. eCollection 2018.

5.

HPV vaccination for victims of childhood sexual abuse.

Garland SM, Subasinghe AK, Jayasinghe YL, Wark JD, Moscicki AB, Singer A, Bosch X, Cusack K, Stanley M.

Lancet. 2015 Nov 14;386(10007):1919-20. doi: 10.1016/S0140-6736(15)00757-6. Epub 2015 Nov 13. No abstract available.

PMID:
26841735
6.

Psychological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis.

Cusack K, Jonas DE, Forneris CA, Wines C, Sonis J, Middleton JC, Feltner C, Brownley KA, Olmsted KR, Greenblatt A, Weil A, Gaynes BN.

Clin Psychol Rev. 2016 Feb;43:128-41. doi: 10.1016/j.cpr.2015.10.003. Epub 2015 Nov 2. Review.

PMID:
26574151
7.

Design strategies to address kinetics of drug binding and residence time.

Cusack KP, Wang Y, Hoemann MZ, Marjanovic J, Heym RG, Vasudevan A.

Bioorg Med Chem Lett. 2015;25(10):2019-27. doi: 10.1016/j.bmcl.2015.02.027. Epub 2015 Mar 5. Review.

PMID:
25782745
8.

Emerging technologies for metabolite generation and structural diversification.

Cusack KP, Koolman HF, Lange UE, Peltier HM, Piel I, Vasudevan A.

Bioorg Med Chem Lett. 2013 Oct 15;23(20):5471-83. doi: 10.1016/j.bmcl.2013.08.003. Epub 2013 Aug 11.

9.

Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].

Jonas DE, Cusack K, Forneris CA, Wilkins TM, Sonis J, Middleton JC, Feltner C, Meredith D, Cavanaugh J, Brownley KA, Olmsted KR, Greenblatt A, Weil A, Gaynes BN.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr.

10.

PTSD as a mediator between lifetime sexual abuse and substance use among jail diversion participants.

Cusack KJ, Herring AH, Steadman HJ.

Psychiatr Serv. 2013 Aug 1;64(8):776-81. doi: 10.1176/appi.ps.000052012.

PMID:
23633122
11.

Joint mobilization acutely improves landing kinematics in chronic ankle instability.

Delahunt E, Cusack K, Wilson L, Doherty C.

Med Sci Sports Exerc. 2013 Mar;45(3):514-9. doi: 10.1249/MSS.0b013e3182746d0a.

PMID:
23034641
12.

Perceived coercion among jail diversion participants in a multisite study.

Cusack KJ, Steadman HJ, Herring AH.

Psychiatr Serv. 2010 Sep;61(9):911-6. doi: 10.1176/ps.2010.61.9.911.

13.

S1P(1) receptor agonists: Assessment of selectivity and current clinical activity.

Cusack KP, Stoffel RH.

Curr Opin Drug Discov Devel. 2010 Jul;13(4):481-8. Review.

PMID:
20597031
14.

Criminal justice involvement, behavioral health service use, and costs of forensic assertive community treatment: a randomized trial.

Cusack KJ, Morrissey JP, Cuddeback GS, Prins A, Williams DM.

Community Ment Health J. 2010 Aug;46(4):356-63. doi: 10.1007/s10597-010-9299-z. Epub 2010 Mar 10.

15.

Therapist fidelity with an exposure-based treatment of PTSD in adults with schizophrenia or schizoaffective disorder.

Long ME, Grubaugh AL, Elhai JD, Cusack KJ, Knapp R, Frueh BC.

J Clin Psychol. 2010 Apr;66(4):383-93. doi: 10.1002/jclp.20657.

16.

Diagnostic practices for traumatized youths: do clinicians incorporate symptom scale results?

Osterberg LD, Jensen-Doss A, Cusack KJ, de Arellano MA.

Community Ment Health J. 2009 Dec;45(6):497-507. doi: 10.1007/s10597-009-9258-8. Epub 2009 Dec 2.

PMID:
19957106
17.

Scalable synthesis and isolation of the four stereoisomers of methyl 1-amino-3-(4-bromophenyl)cyclopentanecarboxylate, useful intermediates for the synthesis of S1P1 receptor agonists.

Wallace GA, Gordon TD, Hayes ME, Konopacki DB, Fix-Stenzel SR, Zhang X, Grongsaard P, Cusack KP, Schaffter LM, Henry RF, Stoffel RH.

J Org Chem. 2009 Jul 3;74(13):4886-9. doi: 10.1021/jo900376b.

PMID:
19489574
18.

Exposure-based cognitive-behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder: a pilot study.

Frueh BC, Grubaugh AL, Cusack KJ, Kimble MO, Elhai JD, Knapp RG.

J Anxiety Disord. 2009 Jun;23(5):665-75. doi: 10.1016/j.janxdis.2009.02.005. Epub 2009 Feb 14.

19.

Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-alpha production.

Cusack K, Allen H, Bischoff A, Clabbers A, Dixon R, Fix-Stenzel S, Friedman M, Gaumont Y, George D, Gordon T, Grongsaard P, Janssen B, Jia Y, Moskey M, Quinn C, Salmeron A, Thomas C, Wallace G, Wishart N, Yu Z.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1722-5. doi: 10.1016/j.bmcl.2009.01.088. Epub 2009 Jan 30.

PMID:
19217782
20.

"Trumping rules" affect diagnoses of persons with severe mental illness.

Grubaugh AL, Cusack KJ, Zinzow HM.

Psychiatr Serv. 2008 Oct;59(10):1219-20. doi: 10.1176/appi.ps.59.10.1219. No abstract available.

PMID:
18832515
21.

Discovery of thieno[2,3-c]pyridines as potent COT inhibitors.

George D, Friedman M, Allen H, Argiriadi M, Barberis C, Bischoff A, Clabbers A, Cusack K, Dixon R, Fix-Stenzel S, Gordon T, Janssen B, Jia Y, Moskey M, Quinn C, Salmeron JA, Wishart N, Woller K, Yu Z.

Bioorg Med Chem Lett. 2008 Sep 15;18(18):4952-5. doi: 10.1016/j.bmcl.2008.08.037. Epub 2008 Aug 14.

PMID:
18755587
22.

Disseminating evidence-based practices for adults with PTSD and severe mental illness in public-sector mental health agencies.

Frueh BC, Grubaugh AL, Cusack KJ, Elhai JD.

Behav Modif. 2009 Jan;33(1):66-81. doi: 10.1177/0145445508322619. Epub 2008 Aug 22.

23.

How many forensic assertive community treatment teams do we need?

Cuddeback GS, Morrissey JP, Cusack KJ.

Psychiatr Serv. 2008 Feb;59(2):205-8. doi: 10.1176/ps.2008.59.2.205.

24.

Workshop-based training in trauma-focused CBT: an in-depth analysis of impact on provider practices.

Jensen-Doss A, Cusack KJ, de Arellano MA.

Community Ment Health J. 2008 Aug;44(4):227-44. Epub 2007 Dec 20.

PMID:
18157693
25.

Targeting trauma-related interventions and improving outcomes for women with co-occurring disorders.

Cusack KJ, Morrissey JP, Ellis AR.

Adm Policy Ment Health. 2008 May;35(3):147-58. Epub 2007 Nov 13.

26.

An update on the South Carolina trauma initiative.

Cusack KJ, Wells CB, Grubaugh AL, Hiers TG, Frueh BC.

Psychiatr Serv. 2007 May;58(5):708-10.

PMID:
17463355
27.

Are there racial differences in the experience of harmful or traumatic events within psychiatric settings?

Cusack KJ, Grubaugh AL, Yim E, Knapp RG, Robins CS, Frueh BC.

Psychiatr Q. 2007 Jun;78(2):101-15.

PMID:
17345158
28.

Screening for PTSD in public-sector mental health settings: the diagnostic utility of the PTSD checklist.

Grubaugh AL, Elhai JD, Cusack KJ, Wells C, Frueh BC.

Depress Anxiety. 2007;24(2):124-9.

PMID:
16892418
29.

Unrecognized trauma and PTSD among public mental health consumers with chronic and severe mental illness.

Cusack KJ, Grubaugh AL, Knapp RG, Frueh BC.

Community Ment Health J. 2006 Oct;42(5):487-500. Epub 2006 Jul 26.

PMID:
16868841
30.

Clinicians' perspectives on cognitive-behavioral treatment for PTSD among persons with severe mental illness.

Frueh BC, Cusack KJ, Grubaugh AL, Sauvageot JA, Wells C.

Psychiatr Serv. 2006 Jul;57(7):1027-31.

PMID:
16816289
31.

Consumers' perceptions of negative experiences and "sanctuary harm" in psychiatric settings.

Robins CS, Sauvageot JA, Cusack KJ, Suffoletta-Maierle S, Frueh BC.

Psychiatr Serv. 2005 Sep;56(9):1134-8.

PMID:
16148329
32.

Patients' reports of traumatic or harmful experiences within the psychiatric setting.

Frueh BC, Knapp RG, Cusack KJ, Grubaugh AL, Sauvageot JA, Cousins VC, Yim E, Robins CS, Monnier J, Hiers TG.

Psychiatr Serv. 2005 Sep;56(9):1123-33.

PMID:
16148328
33.

A 13C NMR approach to categorizing potential limitations of alpha,beta-unsaturated carbonyl systems in drug-like molecules.

Cusack KP, Arnold LD, Barberis CE, Chen H, Ericsson AM, Gaza-Bulseco GS, Gordon TD, Grinnell CM, Harsch A, Pellegrini M, Tarcsa E.

Bioorg Med Chem Lett. 2004 Nov 15;14(22):5503-7.

PMID:
15482913
34.

Cognitive-behavioral treatment for PTSD among people with severe mental illness: a proposed treatment model.

Frueh BC, Buckley TC, Cusack KJ, Kimble MO, Grubaugh AL, Turner SM, Keane TM.

J Psychiatr Pract. 2004 Jan;10(1):26-38. Review.

PMID:
15334985
35.

Trauma history screening in a community mental health center.

Cusack KJ, Frueh BC, Brady KT.

Psychiatr Serv. 2004 Feb;55(2):157-62.

PMID:
14762240
36.

Trauma within the psychiatric setting: a preliminary empirical report.

Cusack KJ, Frueh BC, Hiers T, Suffoletta-Maierle S, Bennett S.

Adm Policy Ment Health. 2003 May;30(5):453-60. No abstract available.

PMID:
12940686
37.

The need for trauma assessment and related clinical services in a state-funded mental health system.

Frueh BC, Cousins VC, Hiers TG, Cavenaugh SD, Cusack KJ, Santos AB.

Community Ment Health J. 2002 Aug;38(4):351-6.

PMID:
12166921
38.

Who needs trauma initiatives? South Carolina!

Cusack KJ, Frueh BC.

Psychiatr Serv. 2001 Aug;52(8):1104-5. No abstract available.

PMID:
11474062
39.

Improving public mental health services for trauma victims in South Carolina.

Frueh BC, Cusack KJ, Hiers TG, Monogan S, Cousins VC, Cavenaugh SD.

Psychiatr Serv. 2001 Jun;52(6):812-4.

PMID:
11376230
40.
41.

15-substituted lanosterols: post-transcriptional suppressors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Anderson JA, Leonard DA, Cusack KP, Frye LL.

Arch Biochem Biophys. 1995 Jan 10;316(1):190-6.

PMID:
7840615
42.

Oxolanosterol oximes: dual-action inhibitors of cholesterol biosynthesis.

Frye LL, Cusack KP, Leonard DA, Anderson JA.

J Lipid Res. 1994 Aug;35(8):1333-44.

43.

32-Methyl-32-oxylanosterols: dual-action inhibitors of cholesterol biosynthesis.

Frye LL, Cusack KP, Leonard DA.

J Med Chem. 1993 Feb 5;36(3):410-6.

PMID:
8426367

Supplemental Content

Loading ...
Support Center